.8B, trading at HK$8.34 on the HKSE. This SniperIQ fundamentals page covers Guangzhou Innogen Pharmaceutl Grp's valuation, profitability (net margin -259.6%), revenue (¥128M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
.8B
Net Margin-259.6%
Revenue (FY25)¥128M

Full research coverage

Frequently Asked Questions

What is Guangzhou Innogen Pharmaceutl Grp's market cap?

Guangzhou Innogen Pharmaceutl Grp (2591) has a market capitalization of approximately HK

.8B, trading at HK$8.34 on the HKSE. Market cap moves with the live share price.

What is Guangzhou Innogen Pharmaceutl Grp's P/E ratio?

Guangzhou Innogen Pharmaceutl Grp's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Guangzhou Innogen Pharmaceutl Grp?

Guangzhou Innogen Pharmaceutl Grp runs a net profit margin of -259.6%, a gross margin of 89.0%, and an operating margin of -254.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Guangzhou Innogen Pharmaceutl Grp generate?

Guangzhou Innogen Pharmaceutl Grp reported revenue of ¥128M for fiscal year 2025, with net income of -¥333M and earnings per share (EPS) of -0.76. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Guangzhou Innogen Pharmaceutl Grp pay a dividend?

Guangzhou Innogen Pharmaceutl Grp does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Guangzhou Innogen Pharmaceutl Grp financially healthy?

Guangzhou Innogen Pharmaceutl Grp carries a debt-to-equity ratio of 0.16x and a current ratio of 2.93x, with a market beta of 1.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Guangzhou Innogen Pharmaceutl Grp a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guangzhou Innogen Pharmaceutl Grp (2591) the key facts are: market cap HK

.8B, revenue ¥128M, 52-week range 6.73-74. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Guangzhou Innogen Pharmaceutl Grp's full fundamentals live

Get Guangzhou Innogen Pharmaceutl Grp's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.